MAIA Biotechnology, Inc.: MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs ("MAIA"), today announced that it has been selected to conduct an

Related Keywords

Solna ,Stockholm ,Sweden ,Dallas ,Texas ,United States ,Chicago ,Illinois ,University Of Texas ,Stephanie Carrington ,Sergei Gryaznov ,Jerryw Shay ,Sergeim Gryaznov ,International Round Table On Nucleosides ,Southwestern Medical Center ,Biotechnology Inc ,Maia Biotechnology Inc ,International Round Table ,Round Table ,Nucleic Acids ,Chief Scientific Officer ,Vlad Vitoc ,Chief Executive ,Driven Telomeric ,Cancer Cells Leads ,Efficient Induction ,Adoptive Immune ,Karolinska Institutet Campus Solna ,Looking Statements ,Maia ,Biotechnology ,Present ,Anticancer ,Ohio ,Platform ,Nternational ,Hound ,Table ,Nucleosides ,Nucleotides ,Nucleic ,Acids ,